跳至主要内容
临床试验/NL-OMON24121
NL-OMON24121招募中不适用

A study to explore the safety, tolerability, pharmacokinetic profile, and potential efficacy of Guanabenz in patients with early childhood onset Vanishing White Matter (VWM)

Amsterdam University Medical Centers, location VUmc, De Boelelaan 1117, 1081HV Amsterdam0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Each patient’s parents/legal guardians must sign an informed consent form (ICF) indicating that they understand the purpose of and procedures required for this study, are willing for their child to participate in the study and attend all scheduled assessments (on site or by video consultation as indicated per protocol), and are willing and able to comply with all study-related procedures, including maintaining contact with the site for at least 1 year, and adhere to the prohibitions and restrictions as specified in the protocol.
  • Note: For each patient, both parents/legal guardians must give written consent.
  • 2.Male or female who has a maximum disease duration of 8 years.
  • 3.Genetically proven VWM with 2 clinically relevant mutations in one of the EIF2B1-5 genes and a brain MRI compatible with the diagnosis.
  • 4.Disease onset before the age of 6 years.
  • 5.Able to stand up and walk at least 10 steps with or without light support of one hand.
  • 6.Lives within reasonable travel distance from Amsterdam.

排除标准

  • 1.Clinically asymptomatic.
  • 2.Comorbidity with another genetic defect.
  • 3.Presence of an unrelated serious condition (eg, developmental anomaly, cardiac, liver or kidney disease).
  • 4.Participation in another clinical study with therapeutic intervention.
  • 5.Unable or unwilling to come to the study site as required by the protocol.
  • 6.Unable to undergo MRI due to metal-containing implants, such as cochlea implant, neurostimulator or pacemaker.
  • 7.Family situation in which adherence to the study medication or follow-up procedures cannot be guaranteed.
  • 8.Known allergy or hypersensitivity to guanabenz or to any of the other components of the formulation used in this study.

研究者

发起方
Amsterdam University Medical Centers, location VUmc, De Boelelaan 1117, 1081HV Amsterdam

相似试验

Guanabenz in VWM | 临床试验